Funding from the 21st Century Cures Act to the FDA will help expedite the drug approval process without sacrificing the accountability and effectiveness of the FDA's standards, said Congressman Frank Pallone, Jr (D-NJ).
In addition to funding for the Nationa Institutes of Health, the 21st Century Cures Act grants $550 million to the FDA for research and innovation specifically for drugs and medical devices, said Congressman Frank Pallone, Jr (D-NJ).
He believes that while this initiative expedite the process for a number of programs and clinical trials, it will maintain the accountability and effectiveness of the FDA’s standards.
“I was at the European Union about a month ago talking to the equivalent of the FDA in the European Union in Brussels and we’re the gold standard,” Mr Pallone said. “We’re the most rigorous process there is for both drugs and medical devices and I think that there are ways that maybe you can streamline that without limiting effectiveness.”
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Dr John McMurray: ESC Congress 2023 Has Something for Everyone
August 22nd 2023Ahead of the European Society of Cardiology (ESC) Congress 2023, John McMurray, MD, FRCP, FESC, professor of medical cardiology at the University of Glasgow, previews some themes and important topics that will be discussed at the meeting.
Read More
Dr Robert Dellavalle Discusses the Importance of Diversity in Clinical Trials
July 2nd 2023Unless all populations are represented adequately in trials, it will be hard to know if a drug works the same in all populations as it does in one specific one, explained Robert Dellavalle, MD, PhD, MSPH, of University of Colorado School of Medicine and Rocky Mountain Regional VA Medical Center.
Read More
2 Clarke Drive
Cranbury, NJ 08512